In neurodegenerative diseases, miRNA-based therapies are being investigated for their ability to modulate key pathological processes, such as tau phosphorylation in Alzheimer’s disease or α-synuclein aggregation in Parkinson’s disease (194, 195). This evidence concerns the gene MAPT and early-onset autosomal dominant Alzheimer disease.